Rocket Pharmaceuticals, Inc. - Common Stock (NQ:RCKT)

2.450 +0.170 (+7.46%)

Delayed Quote Updated: 4:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Rocket Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗

November 28, 2022

Welcome back, trader! It's time to check out the biggest pre-market stock movers that traders will want to know about on Monday!

Via InvestorPlace

Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

November 21, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

This Stock Is Up 106% In 2022 And Analysts Love It, But Jim Cramer Says 'There's Too Much Political Risk' ↗

November 15, 2022

On CNBC’s "Mad Money Lightning Round," Jim Cramer said Rocket Pharmaceuticals Inc (NASDAQ: RCKT) is a "very early stage company that has a lot in the pipe. I tend to like these companies."

Via Benzinga

Analyst Ratings for Rocket Pharmaceuticals ↗

September 30, 2022

Rocket Pharmaceuticals (NASDAQ:RCKT) has observed the following analyst ratings within the last quarter:

Via Benzinga

Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday ↗

November 18, 2022

Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday.

Via Benzinga

Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

November 03, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022 ↗

November 08, 2022

Upgrades

Via Benzinga

Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses

November 03, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗

November 01, 2022

Upgrades

Via Benzinga

$20 Million Bet On Rocket Pharmaceuticals? 3 Stocks Insiders Are Buying ↗

October 12, 2022

Although US crude oil prices traded lower on Wednesday, there were a few notable insider trades.

Via Benzinga

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

October 12, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa

October 10, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock

October 03, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock

October 03, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Citigroup To $47? Plus This Analysts Predict $95 For Papa John's ↗

October 03, 2022

Goldman Sachs cut Citigroup Inc. (NYSE: C) price target from $54 to $47. Citigroup shares fell 0.4% to $41.51 in pre-market trading.

Via Benzinga

Coca-Cola Price Target Cut By This Analyst? Plus Rocket Pharmaceuticals Likely To Rally Around 306% ↗

October 03, 2022

Wells Fargo cut the price target on The Coca-Cola Company (NYSE: KO) from $72 to $66. Wells Fargo analyst Chris Carey maintained an Overweight rating on the stock. Coca-Cola shares rose 0.3% to $56.20...

Via Benzinga

Health Care Company Rocket Pharmaceuticals Announces Acquisition of Renovacor ↗

September 30, 2022

Rocket Pharmaceuticals (NASDAQ:RCKT) has announced an acquisition of Renovacor (AMEX:RCOR) that is expected to be completed in Q1 of 2023.

Via Benzinga

Why F45 Training Shares Climbed 41%; Here Are 84 Biggest Movers From Friday ↗

October 03, 2022

Gainers FingerMotion, Inc. (NASDAQ: FNGR) gained 82.2% to close at $3.37.

Via Benzinga

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

September 30, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference

September 27, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EVOP, STOR, RCKT, RCOR

September 22, 2022

Via ACCESSWIRE

Why Is Renovacor (RCOR) Stock Up 18% Today? ↗

September 20, 2022

Renovacor (RCOR) stock is gaining on Tuesday after announcing that Rocket Pharmaceuticals (RCKT) is acquiring it in an all-stock deal.

Via InvestorPlace

Rocket Pharmaceuticals Buys Renovacor, Strengthening Position In Gene Therapies For Heart Diseases ↗

September 20, 2022

Via Benzinga

RCKT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Merger of Rocket Pharmaceuticals, Inc. Is Fair to Shareholders

September 20, 2022

From Halper Sadeh LLC

Via Business Wire

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

September 20, 2022

From Rocket Pharmaceuticals, Inc. and Renovacor, Inc.

Via Business Wire

Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

September 16, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference

September 06, 2022

From Rocket Pharmaceuticals, Inc.

Via Business Wire

Rocket Pharmaceuticals Stock Scores Rising Relative Strength Upgrade ↗

August 11, 2022

On Thursday, Rocket Pharmaceuticals stock received an upgrade to its Relative Strength (RS) Rating, from 88 to 94.

Via Investor's Business Daily

Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday ↗

September 14, 2022

Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX...

Via Benzinga

Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session ↗

September 13, 2022

Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis.

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.